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Abstract
Background: Accumulating evidence has pointed that a variety of lipids could exert their beneficial actions against
dementia including Alzheimer disease and age-related cognitive decline via diverse signaling pathways.
Endoplasmic reticulum (ER) stress-induced neuronal apoptosis, on the other hand, is a critical factor for
pathogenesis of neurodegenerative diseases such as Alzheimer disease and Parkinson disease, senile dementia, and
ischemic neuronal damage. The present study examined the effects of 1,2-dilinoleoyl-sn-glycero-3-
phosphoethanolamine (DLPhtEtn), a phospholipid, on ER stress-induced neuronal death and age-related cognitive
disorders.
Methods: PC-12 cell viability was assayed before and after treatment with amyloid-b1-40 peptide or thapsigargin in
the presence and absence of DLPhtEtn. A series of behavioral tests were performed for senescence-accelerated
mouse-prone 8 (SAMP8) mice after 7-month oral administration with polyethylene glycol (PEG) or DLPhtEtn and
then, the number of hippocampal neurons was counted.
Results: Amyloid-b1-40 peptide or thapsigargin is capable of causing ER stress-induced apoptosis. DLPhtEtn (30 μM)
significantly inhibited PC-12 cell death induced by amyloid-b1-40 peptide or thapsigargin. In the water maze test,
oral administration with DLPhtEtn (1 mg/kg) for 7 months (three times a week) significantly shortened the
prolonged retention latency for SAMP8 mice. In contrast, DLPhtEtn had no effect on the acquisition and retention
latencies in both the open field test and the passive avoidance test for SAMP8 mice. Oral administration with
DLPhtEtn (1 mg/kg) for 7 months prevented a decrease in the number of hippocampal neurons for SAMP8 mice.
Conclusion: The results of the present study show that DLPhtEtn ameliorates age-related spatial memory decline
without affecting motor activities or fear memory, possibly by protecting hippocampal neuronal death. DLPhtEtn,
thus, might exert its beneficial action against senile dementia and neurodegenerative diseases such as Alzheimer
disease.
Background
Endoplasmic reticulum (ER) stress, i.e., intraluminal
accumulation of unfolded proteins, induces apoptosis by
activating caspase-12 for mice and rats/caspase-4 for
humans, and in turn, the effector caspase-3 [1-3]. Lines
of evidence have pointed to ER stress-induced neuronal
apoptosis as a critical factor for pathogenesis of neuro-
degenerative diseases such as Alzheimer disease and
Parkinson disease, senile dementia, and ischemic neuro-
nal damage [4-9].
Interestingly, gene expression alterations in the sphin-
golipid metabolism pathways such as upregulation of
ceramide and downregulation of glycosphingolipids and
sphingosine 1-phosphate (S1P), are identified during
progression of dementia and Alzheimer’s disease [10].
Increased ceramide and reduced S1P are found with the
Alzheimer brains [11]. Soluble oligomers of amyloid-b
peptide activates cytosolic calcium-dependent phospholi-
pase A2 and sphingomyelinase, causing a ceramide rise
to induce neuronal death responsible for Alzheimer * Correspondence: tomoyuki@hyo-med.ac.jp
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any medium, provided the original work is properly cited.disease [12]. Sphingolipids, thus, may be a mediator for
progression of Alzheimer disease [13-15].
In contrast, the phospholipid phosphatidylcholine and
its metabolites such as cis-unsaturated free fatty acids and
lysophospholipids might enhance cognitive functions.
1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPhtCho)
or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
improves scopolamine-induced impairment of spatial
learning and memory for rats or mild cognitive impair-
ment/dementia for humans [16,17]. Rat hippocampal
synaptic transmission is facilitated via a pathway linked to
phospholipase A2, that hydrolyzes phosphatidylcholine
into cis-unsaturated free fatty acids and lysophosphatidyl-
choline [18]. The cis-unsaturated free fatty acids, arachido-
nic, linoleic, linolenic, and oleic acid, could facilitate
hippocampal synaptic transmission, like long-term poten-
tiation (LTP), a cellular model of learning and memory, by
enhancing activity of nicotinic acetylcholine (ACh) recep-
tors or a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptors via a protein kinase C (PKC) pathway or a
Ca
2+/calmodulin-dependent protein kinase II pathway
[19-25]. Arachidonic acid serves as a retrograde messenger
of LTP [26]. Lysophosphatidylcholine and lysophosphati-
dic acid could also facilitate hippocampal synaptic trans-
mission by targeting nicotinic ACh receptors [27,28].
Moreover, the linoleic acid derivative 8-[2-(2-pentyl-
cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA)
directly and selectively activates PKC-ε, thereby enhancing
activity of presynaptic a7 ACh receptors involving gluta-
mate release, and then leading to facilitation of hippocam-
pal synaptic transmission [29-31]. DCP-LA ameliorates
memory deficits in rat models treated with amyloid-b
peptide or scopolamine [32]. DCP-LA neutralizes mutant
amyloid b peptide-induced impairment of LTP and spatial
learning [33] or protects neurons from oxidative stress-
induced apoptosis by inhibiting caspase-3/-9 activation
[34]. DCP-LA, alternatively, improves age-related spatial
learning deterioration in SAMP8 mice [35]. A variety of
lipids, thus, could exert their beneficial actions against
dementia including Alzheimer disease and age-related
cognitive decline via diverse signaling pathways. The effect
of the phospholipid DLPhtEtn on cognitive disorders,
however, is far from understanding.
SAMP mice such as SAMP1, SAMP2, SAMP3,
SAMP6, SAMP7, SAMP8, and SAMP9 are widely used
as a murine model of accelerated senescence, and senes-
cence-accelerated mouse-resistant (SAMR) mice such as
SAMR1 and SAMR2, that reveal normal aging, are used
as a control for SAMP mice [36,37]. SAMP mice are
shown to exhibit learning and memory disorders along
age-related reduction of choline acetyltransferase activity
[38-40]. The present study aimed at understanding the
effect of DLPhtEtn on neuronal death and age-related
impairment of spatial learning and memory using PC-12
cells and SAMP8 mice.
We show here that DLPhtEtn ameliorates age-related
spatial memory deterioration, at least in part by inhibit-
ing hippocampal neuronal death.
Methods
Animal care
All procedures have been approved by the Animal Care
and Use Committee at Hyogo College of Medicine and
were in compliance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Cell culture
PC-12 cells, obtained from the RIKEN Cell Bank
(Tsukuba, Japan), were cultured in Dulbecco’sm o d i f i e d
Eagle’s medium containing 10% (v/v) fetal bovine
s e r u ma n d1 0 %( v / v )h o r s es e r u m ,p e n i c i l l i n( f i n a l
concentration, 100 U/ml), and streptomycin (final
concentration, 0.1 mg/ml) in a humidified atmosphere
of 5% CO2 and 95% air at 37°C.
Assay of cell viability
PC-12 cells were treated with amyloid-b1-40 peptide
(Peptide Institute Inc., Osaka, Japan) or thapsigargin
(Wako, Osaka, Japan) in the presence and absence of
phospholipids such as DLPhtEtn (Avanti Polar Lipid, Inc.,
Alabaster, AL, USA), 1-linoleoyl-2-palmitoyl-sn-glycero-3-
phosphoethanolamine (LPPhtEtn) (Avanti Polar Lipid,
Inc.), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPhtEtn) (Avanti Polar Lipid, Inc.), 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine (DPPhtEtn) (Avanti
Polar Lipid, Inc.), 1,2-diheptadecanoyl-sn-glycero-3-
phosphoethanolamine (DHPhtEtn) (Avanti Polar Lipid,
Inc.), 1,2-distearoyl -sn-glycero-3-phosphoethanolamine
(DSPhtEtn) (Avanti Polar Lipid, Inc.), or DLPhtCho
(Avanti Polar Lipid, Inc.), dissolved with PEG, and cell
viability was evaluated by a dye staining method using
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) (DOJINDO, Kumamoto, Japan) by the
method as previously described [41].
Animal preparation
Male SAMP8 and SAMR1 mice (age, 4 weeks) were
obtained from Takeda Pharmaceutical Co. (Osaka, Japan),
and 17 SAMP8 mice and 5 SAMR1 mice were used for
experiments. Mice were individually housed in cages at
23 ± 1°C, with a 12-h light/dark cycle (lighting up at 7:00
a.m.), and had free access to pellet food and water.
DLPhtEtn dissolved with PEG (final volume, 0.1 ml) or
PEG alone (final volume, 0.1 ml) was orally administered
(per os) to mice three times a week (Monday, Wednesday,
and Friday) for 7 months prior to experiments. All the
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Behavioral test batteries were run in the order of open
field test, water maze test, and passive avoidance test using
as i n g l em o u s e ,f r o ml e a s ti n v a s i v et om o r ei n v a s i v e ,t o
minimize the effects of the training history, as previously
described [35].
Open field test
Open field box, that is a cube constructed of 30 cm ×
30 cm plastic plate, covered with wooden box to shut
out light, was prepared for an open field test. The open-
field arena was lighted up at 110 lx by an incandescent
lamp fixed on the roof of the box. To avoid outer noise,
a fan, producing a noise of 45 dB, was fixed on the wall
of the box. Horizontal infrared beams run 2 cm above
the floor with a 10-cm interval from two bidirectional
walls, making nine cross stripes, and 4.5 cm above the
floor with a 2.5-cm interval from one wall. The locomo-
tion and rearing activity was assessed by counting the
number for mice to cross the beams at 2 and 4.5 cm,
r e s p e c t i v e l y .M i c ew e r ea l l o w e dt of r e e l ym o v ei nt h e
open-field arena. The initial half time of the test was
performed under the light conditions, and the latter half
time of the test under the dark conditions.
Water maze test
A circular plastic water tank with 90 cm in diameter
and 36 cm in deep was used for a water maze test. The
entire inside of the pool was painted black, and the pool
was filled up to 20 cm from the bottom with water dar-
k e n e db yI n d i ai n ka t2 2 ° C .Ap l a t f o r m( 1 1c mi nd i a -
meter) painted black was placed into water, the top
sinking 0.5 cm below water surface. The pool was put in
a test room, where there were spatial cues that mice
were able to see from the pool. The position of the
marks remained unchanged throughout testing. A plat-
form was located in the constant position, i.e., in the
middle of one quadrant, equidistant from the center and
edge of the pool. Mice were placed into the water,
facing the wall of the pool at one of 5 positions selected
at random, and time from start to escape onto the plat-
form was measured. When succeeded, mice were
allowed to stay on the platform for 10 s. When mice
failed to find the platform within 90 s, the trial was
stopped and mice were put on the platform for 10 s.
Two trials were carried out a day, and the second trial
began 2 min after the end of the first trial. Mice
received the task for consecutive 8 days, and the mean
acquisition latency (time form the start to arrival onto
the plate) from consecutive 2 days was calculated. Seven
days later, the platform was removed and the retention
latency (time from the start to arrival to the place where
the platform had been set) was measured.
Passive avoidance test
A two-compartment step-through passive avoidance
apparatus; a front illuminated chamber (10 cm × 10 cm
floor and wall with 20 cm in height) and a rear dark
chamber (10 cm × 10 cm floor and wall with 20 cm in
height) was used for a passive avoidance test. Each
chamber was separated by a guillotine door and grids
were attached on both the floors. On the first day mice
were put in the light chamber, and the guillotine door
was locked when mice entered the dark chamber fol-
lowed by an electrical stimulation of 0.36 mA for 3 s to
feet, thereafter leaving mice in the chamber for 30 s.
Then, mice were transferred in the light chamber again,
and staying time in the light chamber was measured as
acquisition latency. Next day (24 h later) mice were put
in the light chamber, and staying time in the light
chamber was measured as retention latency.
Measurement of body weight and brain weight
The body weight was measured in SAMR1 and SAMP8
mice every month after oral administration with PEG or
DLPhtEtn (1 mg/kg). Mice, that had taken a series of
behavioral tests, were sacrificed and removed the brains,
and then, each brain weight was measured.
Measurement of hippocampal area
The brain, removed after behavioral tests, was fixed with
formaldehyde and frozen in powdered dry ice. Then,
coronal sections of the brain was made at a thickness of
18 μm using a cryostat (LEICA CM 1800, Germany),
and a series of 8 sections from the beginning of the
section on the rostral side, where the hippocampus was
detectable, towards the caudal side were used for analy-
sis. Hippocampal area both on the left and right sides
was measured using a computer-based image analysis
system (Image J, NIH, Bethesda, MD, USA), and areas
from 8 sections per a mouse were summated.
Counting of hippocampal neurons
All of 8 coronal sections prepared were reacted with a
mouse monoclonal antibody against NeuN (1:500)
(CHEMICON, Billerica, MA, USA), a marker for neu-
rons, followed by an Alexa Fluor 488-conjugated
secondary antibody (1:500) (Invitogen, Carlsbad, CA,
USA). The number of neurons reactive to an anti-NeuN
antibody was counted in the consistent area (142 μm×
192 μm) of the hippocampal CA1 region on both the
left and right side from 8 sections per a mouse and
summated.
Statistical analysis
Statistical analysis was carried out using analysis of var-
iance (ANOVA) followed by Fisher’s Protected Least
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unpaired t-test.
Results
DLPhtEtn prevents PC-12 cell death induced by
amyloid-b1-40 peptide or thapsigargin
Amyloid-b peptide, a neurotoxic factor for Alzheimer
disease, mediates ER stress-induced apoptosis [42].
Amyloid-b1-40 peptide reduced PC12 cell viability in a
concentration (0.2-20 μM)-dependent manner at 48-h
treatment and the maximal effect was obtained with
5μM (data not shown). We, therefore, examined the
effect of a variety of phospholipids on PC-12 cell death
induced by amyloid-b1-40 peptide at 5 μM. Treatment
with amyloid-b1-40 peptide (5 μM) for 48 h reduced PC-
12 cell viability to approximately 40% of basal levels
(Figure 1A). Of bath-applied phospholipids used here
such as DLPhtEtn, LPPhtEtn, DOPhtEtn, DPPhtEtn,
DHPhtEtn, DSPhtEtn, and DLPhtCho at a concentration
of 30 μM, DLPhtEtn alone significantly prevented amy-
loid-b1-40 peptide-induced PC-12 cell death (Figure 1A).
The DLPhtEtn effect was concentration (1-300 μM)-
dependent, reaching the maximum at 30 μM (Figure 1B).
Thapsigargin, depleting Ca
2+ from the ER, is shown to
cause ER stress-induced apoptosis in PC-12 cells [43].
We subsequently examined the effect of DLPhtEtn on
PC-12 cell death induced by thapsigargin. Treatment
with thapsigargin (100 nM) for 24 h reduced cell viabi-
lity to nearly 20% of basal levels, and bath-application
with DLPhtEtn (30 μM) significantly inhibited thapsigar-
gin-induced PC-12 cell death (Figure 1C). Collectively,
these results indicate that DLPhtEtn protects PC-12
cells from apoptotic cell death induced by amyloid-b1-40
peptide or thapsigargin.
DLPhtEtn reverses hyper-motor activities for SAMP8 mice
We next carried out a series of behaviors for mice trea-
t e dw i t hP E G( p e ro s )o rD L P h t E t n( p e ro s )f o r7
months, that include motor activities, spatial learning
and memory, and fear memory. In the open field test to
assess motor activities, locomotion activity for SAMP8
mice treated with PEG increased as compared with the
activity for SAMR1 mice treated with PEG, dominantly
under the light condition (P = 0.0004, F = 8.526 among
SAMR1+PEG group, SAMP8+PEG group, and SAMP8
+DLPhtEtn group for ANOVA test; P = 0.0007 between
SAMR1+PEG group and SAMP8+PEG group for Fish-
er’s PLSD test) (Figure 2A). Rearing activity for SAMP8
mice treated with PEG also increased as compared with
the activity for SAMR1 mice treated with PEG, domi-
nantly under the light condition (P < 0.0001, F =1 0 . 6 3 8
among SAMR1+PEG group, SAMP8+PEG group, and
SAMP8+DLPhtEtn group for ANOVA test; P < 0.0001
between SAMR1+PEG group and SAMP8+PEG group
Figure 1 The effect of DLPhtEtn on PC-12 cell death induced by
amyloid-b1-40 peptide or thapsigargin.( A)P C - 1 2c e l l sw e r et r e a t e d
with amyloid-b1-40 peptide (5 μM) in the absence (Control) and
presence of phospholipids (30 μM) as indicated in serum-free
extracellular solution for 48 h, and cell viability was assayed. Data
represents the mean (± SEM) percentage of basal levels (MTT
intensities of cells untreated with amyloid-b1-40 peptide) (n = 6
independent experiments). **P < 0.01 as compared with control,
unpaired t-test. (B) Cells were treated with amyloid-b1-40 peptide
(5 μM) in the absence (Control) and presence of DLPhtEtn at
concentrations as indicated in serum-free extracellular solution for
48 h, and cell viability was assayed. Data represents the mean (± SEM)
percentage of basal levels (MTT intensities of cells untreated with
amyloid-b1-40 peptide) (n = 6 independent experiments). *P < 0.1,
**P < 0.01 as compared with control, unpaired t-test. (C) Cells were
treated with thapsigargin (100 nM) in the absence (Control) and
presence of DLPhtEtn (30 μM) in serum-free extracellular solution for
24 h, and cell viability was assayed. Data represents the mean (± SEM)
percentage of basal levels (MTT intensities of cells untreated with
amyloid-b1-40 peptide) (n = 6 independent experiments). P value,
unpaired t-test.
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cate that SAMP8 mice exhibit more excess motor activ-
ities than SAMR1 mice.
Locomotion activity for SAMP8 mice treated with
DLPhtEtn (1 mg/kg) was significantly depressed as com-
pared with the activity for SAMP8 mice untreated with
DLPhtEtn under both the light and dark conditions (P =
0.0011 under the light condition and P < 0.0001 under the
dark condition between SAMP8+PEG group and SAMP8
+DLPhtEtn group for Fisher’s PLSD test) (Figure 2A).
Rearing activity for SAMP8 mice treated with DLPhtEtn
(1 mg/kg) was also significantly suppressed as compared
with the activity for SAMP8 mice untreated with
DLPhtEtn under both the light and dark conditions
(P = 0.0010 under the light condition and P <0 . 0 0 0 1
under the dark condition between SAMP8+PEG group
and SAMP8+DLPhtEtn group for Fisher’s PLSD test)
(Figure 2B). DLPhtEtn, thus, reverses hyper-motor activ-
ities for SAMP8 mice.
DLPhtEtn improves spatial memory impairment for
SAMP8 mice
In the water maze test to assess spatial learning and
memory, the acquisition latency for SAMP8 mice trea-
ted with PEG was significantly delayed as compared
with the latency for SAMR1 mice treated with PEG
(P = 0.0003, F = 8.343 among SAMR1+PEG group,
SAMP8+PEG group, and SAMP8+DLPhtEtn group for
ANOVA test; P = 0.0009 between SAMR1+PEG group
and SAMP8+PEG group for Fisher’sP L S Dt e s t )( F i g u r e
3A). DLPhtEtn (1 mg/kg) had no significant effect on
the prolonged latency for SAMP8 mice untreated with
DLPhtEtn (Figure 3A), suggesting no beneficial action of
DLPhtEtn on age-related spatial learning disorders.
T h er e t e n t i o nl a t e n c yf o rS A M P 8m i c et r e a t e dw i t h
PEG was significantly longer than the latency for
SAMR1 mice treated with PEG (P = 0.0482, F = 3.687
among SAMR1+PEG group, SAMP8+PEG group, and
SAMP8+DLPhtEtn group for ANOVA test; P = 0.0421
between SAMR1+PEG group and SAMP8+PEG group
for Fisher’s PLSD test), and DLPhtEtn (1 mg/kg) signifi-
cantly shortened the prolonged latency for SAMP8 mice
untreated with DLPhtEtn, reaching levels similar to the
latency for SAMR1 mice treated with PEG (Figure 3B).
This implies that DLPhtEtn could ameliorate age-related
spatial memory impairment.
DLPhtEtn does not affect fear memory impairment for
SAMP8 mice
In the passive avoidance test to assess fear memory,
there was no significant difference in the acquisition
latency between SAMR1 and SAMP8 mice treated with
PEG, and DLPhtEtn (1 mg/kg) had no effect on the
latency for SAMP8 mice (Figure 4).
The retention latency for SAMR1 mice treated with
PEG was significantly longer than the latency for SAMP8
mice treated with PEG (Figure 4), indicating fear memory
impairment for SAMP8 mice. DLPhtEtn (1 mg/kg) shor-
tened the retention latency for SAMP8 mice, but not
significantly (Figure 4). This suggests that DLPhtEtn does
not influence fear memory impairment for SAMP8 mice.
DLPhtEtn protects hippocampal neuronal death for
SAMP8 mice
Our final attempt was to see whether DLPhtEtn exerts
its protective action against age-related neuronal death
Figure 2 The effect of DLPhtEtn on motor activity. Open field test
was carried out in SAMR1 and SAMP8 mice after oral administration
with PEG or DLPhtEtn (1 mg/kg) for 7 months. The results of
locomotion and rearing activities are shown in (A)a n d( B), respectively.
Values represent the mean (± SEM) number of times from 2-min block
(n = 5 for SAMR1 mice treated with PEG, 10 for SAMP8 mice treated
with PEG, and 7 for SAMP8 mice treated with DLPhtEtn).
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both for SAMP8 and SAMR1 mice was found with
oral administration with PEG or DLPhtEtn (1 mg/kg)
throughout 7 months (Figure 5A). The increase for
SAMP8 mice treated with DLPhtEtn was significantly
greater than the increase for SAMP8 mice untreated
with DLPhtEtn (P = 0.0012, F =7 . 0 4 6a m o n gS A M R 1
+PEG group, SAMP8+PEG group, and SAMP8
+DLPhtEtn group for ANOVA test; P = 0.0143 between
SAMP8+PEG group and SAMP8+DLPhtEtn group for
Fisher’s PLSD test), but there was no significant differ-
ence in the increase between for SAMP8 mice treated
with DLPhtEtn and SAMR1 mice treated with PEG
(Figure 5A).
No significant difference in the brain weight was
found between SAMR1 and SAMP8 mice treated with
PEG, and DLPhtEtn (1 mg/kg) had no effect on the
brain weight for SAMP8 mice (Figure 5B). Likewise,
there was no significant difference in the hippocampal
size between SAMR1 and SAMP8 mice treated with
PEG, and DLPhtEtn (1 mg/kg) did not affect the hippo-
campal size for SAMP8 mice (Figure 6A,6B). Amazingly,
the number of hippocampal neurons for SAMP8 mice
treated with PEG significantly decreased as compared
with that for SAMR1 mice treated with PEG (Figure
6C,6D). DLPhtEtn (1 mg/kg) significantly prevented a
decrease in the number of hippocampal neurons for
SAMP8 mice untreated with DLPhtEtn (Figure 6C,6D).
This accounts for the protective effect of DLPhtEtn
against age-related hippocampal neuronal death.
Discussion
In the in vitro systems, bath-application with DLPhtEtn
inhibited PC-12 cell death induced by amyloid-b1-40
p e p t i d ei nac o n c e n t r a t i o n( 1 - 3 0 0μM)-dependent man-
ner, but such effect was not obtained with the other
phospholipids, LPPhtEtn, DOPhtEtn, DPPhtEtn,
DHPhtEtn, DSPhtEtn, and DLPhtCho. Bath-application
Figure 3 The effect of DLPhtEtn on spatial learning and
memory.( A) Water maze test was carried out in SAMR1 and SAMP8
mice after oral administration with PEG or DLPhtEtn (1 mg/kg) for 7
months, and the acquisition latency was measured. Values represent
the mean (± SEM) acquisition latency from 2-day block (n = 5 for
SAMR1 mice treated with PEG, 10 for SAMP8 mice treated with PEG,
and 7 for SAMP8 mice treated with DLPhtEtn). (B) Seven days later,
the retention latency was measured. Values represent the mean
(± SEM) retention latency from 2-day block (n = 5 for SAMR1 mice
treated with PEG, 10 for SAMP8 mice treated with PEG, and 7 for
SAMP8 mice treated with DLPhtEtn). P values, unpaired t-test.
Figure 4 The effect of DLPhtEtn on fear memory. In the passive
avoidance test, the acquisition latency was measured in SAMR1 and
SAMP8 mice after oral administration with PEG or DLPhtEtn (1 mg/kg)
for 7 months, and 24 h later the retention latency was monitored.
Values represent the mean (± SEM) latency (n = 5 for SAMR1 mice
treated with PEG, 10 for SAMP8 mice treated with PEG, and 7 for
SAMP8 mice treated with DLPhtEtn). P value, unpaired t-test.
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by thapsigargin. It is suggested from these results that
DLPhtEtn prevents ER stress-induced neuronal apopto-
tic cell death. In the in vivo systems, oral administration
with DLPhtEtn inhibited a decrease in the number of
hippocampal neurons for SAMP8 MICE, although the
l i p i dh a dn oe f f e c to nt h eb r a i nw e i g h ta n dt h eh i p p o -
campal size. This indicates that DLPhtEtn still exerts its
protective action against neuronal death in the in vivo
systems. Then, we thought that DLPhtEtn could
improve age-related cognitive decline.
In the water maze test, the acquisition and retention
latencies for SAMP8 mice treated with PEG were signifi-
cantly longer than the latencies for SAMR1 mice treated
with PEG. In the open field test, SAMP8 mice exhibited
more excess motor activities than SAMR1 mice. This
indicates that the prolonged acquisition and prolonged
latencies for SAMP8 mice untreated with DLPhtEtn in
the water maze test is not due to reduced motor activ-
ities, i.e., reduced swimming speed, even though the
swimming speed was not actually measured here.
Accordingly, this confirms age-related decline of spatial
learning and memory for SAMP8 mice. In the water
maze test, oral administration with DLPhtEtn signifi-
cantly shortened the prolonged retention latency for
SAMP8 mice untreated with DLPhtEtn, reaching levels
similar to the latency for SAMR1 mice, although
DLPhtEtn had no efficient effect on the prolonged
acquisition latency. This, taken together with the result
that DLPhtEtn depressed hyper-motor activity for
SAMP8 mice in the open field test, indicates that the
shortened retention latency for SAMP8 mice treated
with DLPhtEtn in the water maze test is not due to
enhanced motor activities, i.e., accelerated swimming
speed. DLPhtEtn, thus, appears to ameliorate age-related
decline of spatial memory.
A study has shown that impairment of spatial learning
and memory disorders for SAMP mice is due to altered
fear memory rather than cognitive impairment [44]. In
the passive avoidance test, the retention latency for
SAMP8 mice treated with PEG was significantly shorter
than that for SAMR1 mice treated with PEG, while
there was no significant difference in the acquisition
latency between SAMP8 and SAMR1 mice. Oral admin-
istration with DLPhtEtn had no effect on both the
acquisition and retention latencies for SAMP8 mice,
excluding the DLPhtEtn action on fear memory. This
implies that DLPhtEtn improves spatial memory dete-
rioration for SAMP8 mice, regardless of fear memory
alteration.
Overall, the results of the present study show that
DLPhtEtn ameliorates age-related spatial memory
d e c l i n e ,p o s s i b l yb yp r o t e c t ing hippocampal neuronal
death. This suggests that DLPhtEtn could be developed
as a promising drug against senile dementia. ER stress-
induced neuronal apoptosis is the major factor for
pathogenesis of neurodegenerative diseases such as
Alzheimer disease and Parkinson disease [4-7,9].
DLPhtEtn rescued PC-12 cells from apoptosis induced
by amyloid-b1-40 peptide or thapsigargin. This, in the
light of the fact that amyloid-b peptide or thapsigargin
causes ER stress-induced apoptosis [42,43], raises the
possibility that DLPhtEtn could also exert its beneficial
Figure 5 Effects of DLPhtEtn on the body and brain weight.( A)
The body weight for SAMR1 and SAMP8 mice was measured every
one month from the beginning of oral administration with PEG or
DLPhtEtn (1 mg/kg) through 7 months. Values represent the mean
(± SEM) body weight (n = 5 for SAMR1 mice treated with PEG, 10
for SAMP8 mice treated with PEG, and 7 for SAMP8 mice treated
with DLPhtEtn). (B) The weight of the brain, isolated from SAMR1
and SAMP8 mice after a series of behavioral tests, was measured.
Values represent the mean (± SEM) brain weight (n = 5 for SAMR1
mice treated with PEG, 10 for SAMP8 mice treated with PEG, and 7
for SAMP8 mice treated with DLPhtEtn).
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tive diseases.
In conclusion, the results of the present study show
that DLPhtEtn is capable of improving age-related spa-
tial memory deterioration, at least in part by preventing
neuronal cell death.
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